Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume 58, Issue 1, Pages 89-95
Publisher
Informa UK Limited
Online
2016-07-25
DOI
10.1080/10428194.2016.1187269
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ropeginterferon alfa-2b, a novel IFN -2b, induces high response rates with low toxicity in patients with polycythemia vera
- (2015) H. Gisslinger et al. BLOOD
- Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia
- (2015) Gabriela M. Baerlocher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
- (2013) H. Gisslinger et al. BLOOD
- JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug
- (2013) E. T. Kuriakose et al. HAEMATOLOGICA
- Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea
- (2013) Emma Verner et al. LEUKEMIA & LYMPHOMA
- Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN
- (2012) Elisabetta Antonioli et al. AMERICAN JOURNAL OF HEMATOLOGY
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
- (2011) A. Alvarez-Larran et al. BLOOD
- Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia
- (2011) Luigi Gugliotta et al. LEUKEMIA RESEARCH
- Hydroxyurea induced oscillations in twelve patients with polycythemia vera
- (2010) J. Tauscher et al. HAEMATOLOGICA
- Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
- (2009) G. Barosi et al. BLOOD
- A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process
- (2009) Giovanni Barosi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
- Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms
- (2008) J-J Kiladjian et al. LEUKEMIA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started